Library · Reproductive · Treatment of advanced prostate cancer
Degarelix
Firmagon, FE200486, ASP3550
GnRH receptor antagonist approved (Firmagon) for advanced prostate cancer. Rapidly lowers testosterone without the initial surge seen with GnRH agonists, giving immediate hormonal control.
Research score 85/100. Reference only, not a dose.
- Hormone Regulation
- Anti-cancer
- Fertility Enhancement
- Testosterone Suppression
- US status
- Prescription Only
- Approval
- FDA + EMA Approved
- Evidence
- FDA approved for advanced prostate cancer. Comparative studies vs GnRH agonists.
- Research score
- 85 / 100
- Indication
- Prostate Cancer
- Origin
- Denmark
- Source category
- Reproductive System
- Status group
- Approved / prescription
Mechanism
Competitively blocks pituitary GnRH receptors, cutting LH and FSH release and suppressing testosterone within 24–48 hours, without the flare caused by agonist drugs.
Safety file
Injection-site pain and redness are very common; hot flashes, weight gain, and liver enzyme rises can occur, with a better cardiovascular profile than GnRH agonists.
- Injection site reactions
- Hot flashes
- Weight increase
- Elevated liver enzymes
- Fatigue